|
|
|
|
|
Currently provisions in many policies require a much greater co-payment for oral drugs. |
|
|
|
|
"My role as a myeloma specialist is to treat patients with the newest, most-effective treatments," said Dr Arthur Molina, Ochsner’s Director of Bone Marrow Transplantation and Hematological
Malignancies. "I am concerned when patients tell me they would rather have an older, less tolerable drug because
their insurance plan will reimburse them at a higher rate." |
|
|
|
|
Principles Emphasize the Three "R's" of Health Care: Research, Reimbursement and Resources |
|
|
|
|
A patient "Statement of Principles" was unveiled at the ASCO Meeting in Orlando, Florida. The principles emphasize equal insurance coverage, prevention research, continued innovation, early approvals, and expanded access to experimental drugs. Click "More" to read the Principles and find out how to register your support. |
|
|
|
|
On April 15th, The New York Times published an article on the inequities in insurance coverage for oral drugs when compared to coverage of intravenous drugs. Today, April 20, Susie Novis' letter to the editor of the Times, stating the IMF's position on insurance inequities, was published. |
|
|
print
back to top